The Future of Biosimilars: Q&A with Matt Erick

Wed, 24 Jul 2024
Posted by: Biocon Biologics
The biosimilars market may be off to a slow start, but experts expect 2024 to be a big moment for the market. Matt Erick, chief commercial officer of advanced markets at Biocon Biologics, discusses the current state of the market and how it may change in the coming months. Pharmaceutical Executive: What are the headwinds and tailwinds for the biosimilars market in 2024?
Author:
Biocon Biologics